Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Danielle Brazel,1 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako NagasakaDepartment of Medi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brazel D, Nagasaka M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	amivantamab epidermal growth factor receptor mesenchymal-epithelial transition factor met non-small cell lung cancer tyrosine kinase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0e20141364c04747a6e6f425e0a36f81
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0e20141364c04747a6e6f425e0a36f81
record_format	dspace
spelling	oai:doaj.org-article:0e20141364c04747a6e6f425e0a36f812021-12-02T19:17:36ZSpotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer1179-2728https://doaj.org/article/0e20141364c04747a6e6f425e0a36f812021-12-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-amivantamab-jnj-61186372-for-egfr-exon-20-insertions-posi-peer-reviewed-fulltext-article-LCTThttps://doaj.org/toc/1179-2728Danielle Brazel,1 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako NagasakaDepartment of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, 101 The City Drive South, Orange, CA, 92868, USAEmail nagasakm@hs.uci.eduAbstract: Non-small cell lung cancer (NSCLC) patients demonstrating sensitizing oncogenic driver mutations have derived clinical benefit from targeted therapy. EGFR mutations constitutively activate the signaling pathway, leading to prosurvival and antiapoptotic signals. Classic sensitizing EGFR mutations, such as exon 19 deletions and exon 21 L858R point mutations, respond well to tyrosine kinase inhibitors (TKIs). On the other hand, EGFR exon 20 in-frame insertions are observed in 4– 12% of EGFR-mutated NSCLC and are resistant to targeted therapy with TKIs. In May 2021, the Federal Drug Administration (FDA) provided accelerated approval to amivantamab (Rybrevant) in adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after treatment with platinum-based chemotherapy. Here, we discuss properties of amivantamab, clinical trial results, and management of patients with EGFR exon 20 insertion mutated NSCLC.Keywords: amivantamab, epidermal growth factor receptor, mesenchymal-epithelial transition factor, MET, non-small cell lung cancer, tyrosine kinase inhibitorsBrazel DNagasaka MDove Medical Pressarticleamivantamabepidermal growth factor receptormesenchymal-epithelial transition factormetnon-small cell lung cancertyrosine kinase inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 12, Pp 133-138 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	amivantamab epidermal growth factor receptor mesenchymal-epithelial transition factor met non-small cell lung cancer tyrosine kinase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	amivantamab epidermal growth factor receptor mesenchymal-epithelial transition factor met non-small cell lung cancer tyrosine kinase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Brazel D Nagasaka M Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
description	Danielle Brazel,1 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako NagasakaDepartment of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, 101 The City Drive South, Orange, CA, 92868, USAEmail nagasakm@hs.uci.eduAbstract: Non-small cell lung cancer (NSCLC) patients demonstrating sensitizing oncogenic driver mutations have derived clinical benefit from targeted therapy. EGFR mutations constitutively activate the signaling pathway, leading to prosurvival and antiapoptotic signals. Classic sensitizing EGFR mutations, such as exon 19 deletions and exon 21 L858R point mutations, respond well to tyrosine kinase inhibitors (TKIs). On the other hand, EGFR exon 20 in-frame insertions are observed in 4– 12% of EGFR-mutated NSCLC and are resistant to targeted therapy with TKIs. In May 2021, the Federal Drug Administration (FDA) provided accelerated approval to amivantamab (Rybrevant) in adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after treatment with platinum-based chemotherapy. Here, we discuss properties of amivantamab, clinical trial results, and management of patients with EGFR exon 20 insertion mutated NSCLC.Keywords: amivantamab, epidermal growth factor receptor, mesenchymal-epithelial transition factor, MET, non-small cell lung cancer, tyrosine kinase inhibitors
format	article
author	Brazel D Nagasaka M
author_facet	Brazel D Nagasaka M
author_sort	Brazel D
title	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
title_short	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
title_full	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
title_fullStr	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
title_full_unstemmed	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
title_sort	spotlight on amivantamab (jnj-61186372) for egfr exon 20 insertions positive non-small cell lung cancer
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0e20141364c04747a6e6f425e0a36f81
work_keys_str_mv	AT brazeld spotlightonamivantamabjnj61186372foregfrexon20insertionspositivenonsmallcelllungcancer AT nagasakam spotlightonamivantamabjnj61186372foregfrexon20insertionspositivenonsmallcelllungcancer
_version_	1718376896979271680

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Ejemplares similares